About: Larry W Kwak

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Larry W Kwak Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher (ORCID 0000-0002-1884-5349)

Attributes	Values
rdf:type	Item
field of work	wds:Q90287448-729C2450-40EB-4197-8FEB-C27B77C3C7BA wds:Q90287448-8AF3C4C7-9424-4B6E-AA59-981F4D51E2E2 wds:Q90287448-9DF369D0-562A-4A05-B29E-DB3942805336 wds:Q90287448-B9976406-4BF4-40A6-8F93-61AB3D88DA63 wds:Q90287448-C148C04B-1CA6-4F1A-AD27-8D4AED18AB54 wds:Q90287448-F968AE29-8726-48AF-AFD1-D2EEF35FC77F
field of work	hematology vaccine myeloid neoplasm oncology immunology lymphoma
description	wetenschapper (nl) дослідник (uk) باحت (ary) Odborník v oblasti hematologie, onkologie a imunologie, specializuje se na výzkum lymfomů a myelomů a na vývoj vakcín proti rakovině. Publikace v oboru. (cs) researcher (ORCID 0000-0002-1884-5349) (en)
rdfs:label	Larry Kwak (cs) Larry W Kwak (en) Larry W Kwak (nl)
skos:prefLabel	Larry Kwak (cs) Larry W Kwak (en) Larry W Kwak (nl)
name	Larry Kwak (cs) Larry W Kwak (en) Larry W Kwak (nl)
Scopus author ID	wds:Q90287448-0AA91295-27FE-4F7A-95BE-C5CE1C5AA53F
Scopus author ID	7005345345
given name	wds:Q90287448-093D694C-B2F2-45ED-9A82-61985523C9C3
given name	Larry
instance of	wds:Q90287448-BF6A90C6-C9C8-4366-8D24-59B079C2524D
NL CR AUT ID	wds:Q90287448-913BC97F-ED42-40AD-B3A2-48E290984E59
instance of	Homo sapiens
NL CR AUT ID	ntk20221161330
skos:altLabel	Larry Kwak (en)
occupation	wds:Q90287448-02f7a720-c809-44b9-99fc-966de3652f77 wds:Q90287448-32404bfe-a22f-4ec0-bcfe-eb6cd6e25215 wds:Q90287448-AE2BF3DC-75B1-40EE-ACC6-60F00F24C809 wds:Q90287448-d5575317-74c5-4ec9-ab64-4ffdfc98e156
languages spoken, written or signed	wds:Q90287448-45348432-ec69-4697-a0c7-61e478790e6e
VIAF ID	wds:Q90287448-c7b7febe-93f8-440d-b79a-9777360e7936
date of birth	wds:Q90287448-3843F4FA-793F-4D9C-BBF0-581256AB9803
VIAF ID	http://viaf.org/viaf/72889040
occupation	scientist oncologist hematologist researcher
languages spoken, written or signed	English
VIAF ID	72889040
date of birth	1959-01-01 00:00:00Z (xsd:dateTime)
ORCID iD	wds:Q90287448-DB4E582E-BDC9-4072-8C95-807AC188C0D4
ORCID iD	https://orcid.org/0000-0002-1884-5349
ORCID iD	0000-0002-1884-5349
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q90287448
is author of	Mammalian defensins in immunity: more than just microbicidal Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma A modified human ELISPOT assay to detect specific responses to primary tumor cell targets Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaques Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo Therapeutic idiotype vaccines in B lymphoproliferative diseases Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes A novel proteoliposomal vaccine elicits potent antitumor immunity in mice Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities Vaccination strategies for lymphomas Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis Targeting cell surface β2 -microglobulin by pentameric IgM antibodies Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software